Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA.
J Clin Oncol. 2011 Jun 20;29(18):2466-73. doi: 10.1200/JCO.2010.32.4079. Epub 2011 May 16.
To compare characteristics and outcomes of breast cancer in women with and without a history of radiation therapy (RT) for Hodgkin's lymphoma (HL).
Women with breast cancer diagnosed from 1980 to 2006 after RT for HL were identified from eight North American hospitals and were matched three-to-one with patients with sporadic breast cancer by age, race, and year of breast cancer diagnosis. Information on patient, tumor and treatment characteristics, and clinical outcomes was abstracted from medical records.
A total of 253 patients with breast cancer with a history of RT for HL were matched with 741 patients with sporadic breast cancer. Median time from HL to breast cancer diagnosis was 18 years. Median age at breast cancer diagnosis was 42 years. Breast cancer after RT for HL was more likely to be detected by screening, was more likely to be diagnosed at an earlier stage, and was more likely to be bilateral at diagnosis. HL survivors had an increased risk of metachronous contralateral breast cancer (adjusted hazard ratio [HR], 4.3; 95% CI, 1.7 to 11.0) and death as a result of any cause (adjusted HR, 1.9; 95% CI, 1.1 to 3.3). Breast cancer-specific mortality was also elevated, but this difference was not statistically significant (adjusted HR, 1.6; 95% CI, 0.7 to 3.4).
In women with a history of RT for HL, breast cancer is diagnosed at an earlier stage, but these women are at greater risk for bilateral disease and are more likely to die as a result of causes other than breast cancer. Our findings support close follow-up for contralateral tumors in these patients and ongoing primary care to manage comorbid conditions.
比较有和无霍奇金淋巴瘤(HL)放疗史的女性乳腺癌的特征和结局。
从 8 家北美医院中确定了 1980 年至 2006 年间因 HL 接受放疗后诊断出患有乳腺癌的女性,并通过年龄、种族和乳腺癌诊断年份与散发性乳腺癌患者三对一匹配。从病历中提取患者、肿瘤和治疗特征以及临床结局的信息。
共 253 例因 HL 放疗后患有乳腺癌的患者与 741 例散发性乳腺癌患者相匹配。从 HL 到乳腺癌诊断的中位时间为 18 年。乳腺癌诊断时的中位年龄为 42 岁。HL 放疗后乳腺癌更可能通过筛查发现,更可能在早期诊断,且更可能在诊断时为双侧。HL 幸存者发生异时性对侧乳腺癌的风险增加(调整后的危险比[HR],4.3;95%可信区间,1.7 至 11.0)和任何原因导致的死亡风险增加(调整后的 HR,1.9;95%可信区间,1.1 至 3.3)。乳腺癌特异性死亡率也升高,但差异无统计学意义(调整后的 HR,1.6;95%可信区间,0.7 至 3.4)。
在有 HL 放疗史的女性中,乳腺癌的诊断更早,但这些女性发生双侧疾病的风险更高,死于乳腺癌以外原因的可能性更大。我们的发现支持对这些患者的对侧肿瘤进行密切随访,并持续进行初级保健以管理并存疾病。